133191-10-3Relevant articles and documents
EXTENDED HALF-LIFE G-CSF AND GM-CSF VITAMIN D CONJUGATES
-
Paragraph 00472-00474, (2021/04/23)
The invention provides non-hormonal Vitamin D conjugated to G-CSF or compounds with G-CSF activity or GM-CSF or compounds having GM-CSF activity singly or in combination that result in increased absorption, bioavailability or circulating half-life when compared to non- conjugated forms.
RNAi VITAMIN D CONJUGATES
-
Paragraph 0177, (2016/05/24)
The invention provides non-hormonal vitamin D conjugated to therapeutic RNA compounds that result in the compounds having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups
INSULIN VITAMIN D CONJUGATES
-
Paragraph 0180, (2016/05/19)
The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are couple
THERAPEUTIC VITAMIN D CONJUGATES
-
Paragraph 0236, (2016/05/19)
The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are couple
